Free Trial

Checkpoint Therapeutics Q4 2023 Earnings Report

Checkpoint Therapeutics logo
$4.04 -0.01 (-0.12%)
As of 12:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Checkpoint Therapeutics EPS Results

Actual EPS
-$1.10
Consensus EPS
-$0.74
Beat/Miss
Missed by -$0.36
One Year Ago EPS
N/A

Checkpoint Therapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.09 million
Beat/Miss
Missed by -$80.00 thousand
YoY Revenue Growth
N/A

Checkpoint Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Checkpoint Therapeutics Earnings Headlines

Checkpoint Therapeutics reports FY24 EPS ($1.42) vs ($3.17) last year
Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Checkpoint Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Checkpoint Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Checkpoint Therapeutics and other key companies, straight to your email.

About Checkpoint Therapeutics

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

View Checkpoint Therapeutics Profile

More Earnings Resources from MarketBeat